Crossmark

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Crossref DOI link: https://doi.org/10.1186/s12943-022-01496-x

Published Online: 2022-02-04

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hortal, Alejandro M.

Oeste, Clara L.

Cifuentes, Claudia

Alcoceba, Miguel

Fernández-Pisonero, Isabel

Clavaín, Laura

Tercero, Rut

Mendoza, Pilar

Domínguez, Verónica

García-Flores, Marta

Pintado, Belén

Abia, David

García-Macías, Carmen

Navarro-Bailón, Almudena

Bustelo, Xosé R.

González, Marcos

Alarcón, Balbino http://orcid.org/0000-0001-7820-1070
Funding

Funding for this research was provided by:

Fundación Científica Asociación Española Contra el Cáncer (GC16173472GARC)

Ministerio de Ciencia, Innovación y Universidades (PID2019-104935RB-I00)

H2020 European Research Council (ERC 2013-Advanced Grant 33476)

Instituto de Salud Carlos III (CB16/12/00233, CB16/12/00351)

Consejería de Educación, Junta de Castilla y León (GRS 2036/A/19)
License Information

Text and Data Mining valid from 2022-02-04

Version of Record valid from 2022-02-04
More Information

Article History

Received: 8 October 2021

Accepted: 23 December 2021

First Online: 4 February 2022

Declarations

:

: All animal experiments were carried out at the facilities of the Centro de Biología Molecular Severo Ochoa in accordance with national and European guidelines. All the procedures were approved by the ethical committee of the Centro de Biología Molecular Severo Ochoa (approval number: ceea-cbmso-16-02-2015). Blood samples from volunteer CLL patients were obtained from the Hematology Unit of the Salamanca University Hospital after providing written informed consent.

: Written informed consent was obtained from all patients.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below